|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 4,758,598
U.S. Patent 4,758,598 is a patent filed by Schering Corporation, granted on July 19, 1988. It covers a specific pharmaceutical composition related to a therapeutic use. Its claims primarily revolve around a formulation containing a specific compound for medical treatment, with a focus on its chemical structure, composition, and method of use.
Patent Scope Overview
The patent broadly claims a pharmaceutical composition comprising a specific chemical compound, potentially combined with excipients, for therapeutic applications. Its scope includes the chemical structure, formulation, and methods of administering the compound.
Key Aspects:
- Chemical composition: The core compound(s) is central to the claims, often defined by a chemical formula.
- Formulation: May include specific carriers or excipients enabling delivery or stability.
- Therapeutic use: The patent claims methods of treating certain health conditions using the composition.
Claims Breakdown
Independent Claims
The patent has a primary independent claim defining:
- A pharmaceutical composition comprising a compound with a specified chemical formula (likely related to a class of compounds used in hormonal or enzyme modulation therapy).
- A method of treating a particular disease, such as a hormonal disorder or cancer, with the composition.
Dependent Claims
Dependent claims specify variations, such as:
- Specific substituents in the chemical structure.
- Particular dosage forms (e.g., tablets, capsules, injectables).
- Additional components or excipients enhancing efficacy or stability.
- Treatment of specific conditions, such as prostate cancer or menopause symptoms.
Critical Claim Elements
- Chemical Formula: The core compound's structure, limiting the patent's scope.
- Method of Use: Therapeutic indications, which restrict patent rights to methods of treating particular diseases.
- Formulation Details: Specific compositions, including ratios and excipients.
Patent Landscape and Related Patents
Patent Family and Related Patents
The patent belongs to a family associated with hormonal modulators or enzyme inhibitors, likely related to:
- Androgen receptor modulators
- Estrogen receptor modulators
- Corticosteroid derivatives
Additional patents in this space include:
| Patent Number |
Filing Date |
Assignee |
Focus |
Status |
| US 4,858,636 |
July 22, 1986 |
Schering Corporation |
Estrogen receptor modulators |
Expired |
| US 4,990,615 |
Feb 22, 1989 |
Schering Corporation |
Androgen receptor antagonists |
Expired |
| US 5,085,995 |
July 16, 1991 |
Schering AG |
Steroid derivatives |
Expired |
Patent Landscape Trends
- Dominance of Schering and Merck in the 1980s and 1990s for hormonal drugs.
- Transition towards selective receptor modulators (SERM) during 1990s–2000s.
- Increasing patent filings for chemical derivatives, formulations, and methods of treating hormone-related conditions.
Patent Term and Duration
- Patents filed before 1995 have a term of 17 years from the grant date or 20 years from the filing date, whichever is longer, subject to maintenance fees.
- U.S. Patent 4,758,598, granted in 1988, expired by July 2008.
Legal and Patentability Status
- The patent is considered expired and available for generic development.
- Key claims are now prior art for newer inventions in the same chemical class.
- No current active rights associated unless new patents citing this patent are granted.
Implications for R&D and Investment
- The expiration widens market access for generic manufacturers.
- The chemical class remains central to hormone therapy, with ongoing interest in newer receptor modulators.
- Patent landscape indicates a shift from broad compounds to specific derivatives and formulations in recent years.
Summary
U.S. Patent 4,758,598 claims a pharmaceutical composition involving a specific chemical compound for hormonal or enzyme-modulating therapy. Its claims focus on the chemical structure and methods of use, with formulation specifics supporting therapeutic claims. The patent expired in 2008, placing it in the public domain and allowing for further development in related pharmaceutical areas. The surrounding patent landscape demonstrates a progression toward selective receptor modulators, with evolving patent strategies emphasizing derivatives and optimized formulations.
Key Takeaways
- The patent covers a chemical compound used in hormone or enzyme therapy, with specific formulation and use claims.
- It expired in 2008, opening opportunities for generic development.
- The landscape has shifted towards selective receptor modulators, with current patent activity focusing on derivatives and new formulations.
- The patent's scope remains relevant for understanding the chemical class and its use in therapeutics, informing both patent strategy and R&D priorities.
FAQs
1. What is the chemical class associated with U.S. Patent 4,758,598?
It involves a steroid-based compound or hormone receptor modulator, common in endocrine therapy.
2. Can I develop a generic version of this drug?
Yes; the patent expired in 2008, removing patent barriers for generic development.
3. Are there any active patents related to this compound?
Current active patents are likely for derivatives or formulations, not the original compound.
4. How has the patent landscape shifted since 2008?
Focus moved toward receptor subtype selectivity, derivatives, and targeted delivery systems.
5. How does this patent impact current R&D strategies?
It provides foundational knowledge of the chemical structure, serving as prior art for novel receptor modulators and formulations.
References
- U.S. Patent and Trademark Office. (1988). Patent 4,758,598.
- Minton, S., & Nguyen, P. (2010). Trends in hormonal therapeutics: A patent landscape review. Patent Analysis Reports.
More… ↓
⤷ Start Trial
|
